Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cornell Maps Clinically Meaningful Ortho Device Attributes

This article was originally published in The Gray Sheet

Executive Summary

An FDA-funded project lead by Cornell researchers will focus on applying information from the International Consortium of Orthopedic Registries “to create a worldwide attribute and characteristic database” for orthopedic devices.

You may also be interested in...

FDA To Issue Final Device Post-Market Surveillance Plan In February

The device center plans to publish the final version of its national device post-market surveillance strategy and select a third-party group to run its MDEpiNet public-private partnership by the end of February.

Metal-On-Metal Hip Post-market Studies Behind Schedule, NEJM Article Highlights

Delays in getting FDA-ordered surveillance studies up and running for hip implants should be addressed at an advisory panel this week, researchers from the Pew Health Group and Cornell argue.

Midwest Hospitals Prepare For Stent Unique-Device-Identifier Demo

The FDA-funded effort out of the Mercy health care system, consisting of 31 hospitals and 200 outpatient facilities in Missouri, Arkansas, Oklahoma and Kansas*, is intended as a demonstration project to help troubleshoot UDIs before a mandatory nationwide system is launched. It is one of two UDI demos in the works in advance of FDA regulations.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts